The current therapeutic strategies for the management of patients with cirrhosis rely on the prevention or treatment of specific complications. The removal of the causative agents (i.e., viruses or alcohol) prevents decompensation in the vast majority of patients with compensated cirrhosis. In contrast, even when etiological treatment has been effective, a significant proportion of patients with decompensated cirrhosis remains at risk of further disease progression. Therefore, therapies targeting specific key points in the complex pathophysiological cascade of decompensated cirrhosis could represent a new approach for the management of these severely ill patients. Some of the interventions currently employed for treating or preventing specific complications of cirrhosis or used in other diseases (i.e., poorly absorbable oral antibiotics, statins, albumin) have been proposed as potential disease‐modifying agents in cirrhosis (DMAC) since clinical studies have shown their capacity of improving survival. Additional multicenter, large randomized clinical trials are awaited to confirm these promising results. Finally, new drugs able to antagonize key pathophysiological mechanisms are under pre‐clinical development or at the initial stages of clinical assessment.

Zaccherini G., Tufoni M., Bernardi M., Caraceni P. (2021). Prevention of cirrhosis complications: Looking for potential disease modifying agents. JOURNAL OF CLINICAL MEDICINE, 10(19), 4590-4609 [10.3390/jcm10194590].

Prevention of cirrhosis complications: Looking for potential disease modifying agents

Zaccherini G.;Tufoni M.;Bernardi M.;Caraceni P.
Writing – Review & Editing
2021

Abstract

The current therapeutic strategies for the management of patients with cirrhosis rely on the prevention or treatment of specific complications. The removal of the causative agents (i.e., viruses or alcohol) prevents decompensation in the vast majority of patients with compensated cirrhosis. In contrast, even when etiological treatment has been effective, a significant proportion of patients with decompensated cirrhosis remains at risk of further disease progression. Therefore, therapies targeting specific key points in the complex pathophysiological cascade of decompensated cirrhosis could represent a new approach for the management of these severely ill patients. Some of the interventions currently employed for treating or preventing specific complications of cirrhosis or used in other diseases (i.e., poorly absorbable oral antibiotics, statins, albumin) have been proposed as potential disease‐modifying agents in cirrhosis (DMAC) since clinical studies have shown their capacity of improving survival. Additional multicenter, large randomized clinical trials are awaited to confirm these promising results. Finally, new drugs able to antagonize key pathophysiological mechanisms are under pre‐clinical development or at the initial stages of clinical assessment.
2021
Zaccherini G., Tufoni M., Bernardi M., Caraceni P. (2021). Prevention of cirrhosis complications: Looking for potential disease modifying agents. JOURNAL OF CLINICAL MEDICINE, 10(19), 4590-4609 [10.3390/jcm10194590].
Zaccherini G.; Tufoni M.; Bernardi M.; Caraceni P.
File in questo prodotto:
File Dimensione Formato  
jcm-10-04590.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 936.34 kB
Formato Adobe PDF
936.34 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/863556
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact